Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252833 | 0.78 | CYP2A6 (0.53) | CYP2A6PDPK1NPC1RAB9ALOXL2 | |
| SCHEMBL2715410 | 0.78 | CYP2A6 (0.53) | CYP2A6PDPK1LOXL2SMPD3ADRB2 | |
| SCHEMBL3386179 | 0.78 | CYP2A6 (0.53) | CYP2A6PDPK1LOXL2SMPD3ADRB2 | |
| SCHEMBL20153302 | 0.78 | CYP2A6 (0.54) | CYP2A6PDPK1NPC1RAB9ALOXL2 | |
| SCHEMBL7079127 | 0.75 | PDPK1 (0.67) | CYP2A6PDPK1RAB9ALOXL2ADRB2 | |
| SCHEMBL7609803 | 0.74 | PDPK1 (0.60) | CYP2A6PDPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3327398 | 0.74 | CYP2A6 (0.62) | CYP2A6PDPK1RAB9ALOXL2SMPD3 | |
| SCHEMBL16159900 | 0.74 | CYP2A6 (0.53) | CYP2A6PDPK1RAB9ALOXL2SMPD3 | |
| SCHEMBL21282891 | 0.74 | CYP2A6 (0.49) | CYP2A6PDPK1LOXL2SMPD3ADRB2 | |
| SCHEMBL3389168 | 0.74 | CYP2A6 (0.49) | CYP2A6PDPK1LOXL2SMPD3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| WO-2025015420-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-01-23 | — | — | WO | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CYP2A6 3349/4885PDPK1 2634/4885NPC1 1367/4885 |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | FAAH, FAAH2, MGLL | CYP2A6 232/4885PDPK1 1510/4885NPC1 1197/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | CYP2A6 232/4885PDPK1 1510/4885NPC1 1197/4885 |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | CYP2A6 1206/4885PDPK1 4680/4885NPC1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.